Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UL51

UPID:
HCN2_HUMAN

ALTERNATIVE NAMES:
Brain cyclic nucleotide-gated channel 2

ALTERNATIVE UPACC:
Q9UL51; O60742; O60743; O75267; Q9UBS2

BACKGROUND:
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2, alternatively named Brain cyclic nucleotide-gated channel 2, is integral for generating pacemaker currents in both cardiac and neuronal tissues. It preferentially transports potassium ions over sodium and is capable of ammonium transport. The channel's function is modulated by the intracellular environment, including chloride ion concentration and pH levels.

THERAPEUTIC SIGNIFICANCE:
Dysfunction in this protein is associated with diseases such as Epilepsy, idiopathic generalized 17, and familial Febrile seizures, 2. The exploration of Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2's role offers promising avenues for the development of novel treatments for these epilepsy-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.